Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent
Biotech execs express concerns over FDA changes, NIH cuts, and Trump’s tariffs. Industry confidence low amid poor funding environment and dead IPO market in 2025.
Related Articles
FDA expects ‘timely availability’ of Covid shots as advisors update formula recommendation
FDA vaccine advisors unanimously recommend JN.1-lineage Covid-19 vaccine for upcoming season. CBER Director Vinay Prasad emphasizes transparency in vaccine discussions.
Why Regeneron is buying 23andMe
Regeneron has a long history with its gene-sequencing efforts, which likely provides some hints as to why the biotech saw the 23andMe deal as worthwhile.
Post-Hoc: AI bio needs to heed the overhyped history of CRISPR
Beam Therapeutics CEO John Evans warns against AI hype in drug development, drawing parallels to past CRISPR expectations, responding to DeepMind CEO’s disease cure claims.
FDA adcomm narrowly votes against UroGen’s bladder cancer drug, calls for RCTs
The FDA’s Oncologic Drugs Advisory Committee on Wednesday voted 5 to 4 against UroGen’s mitomycin as an option for low-grade intermediate-risk non-muscle invasive bladder cancer.
FDA asks Covid vaccine makers to add more myocarditis data to labels
FDA requests Moderna, Pfizer/BioNTech add safety warnings about myocarditis risk to COVID-19 vaccines, with specific rates for different age groups, including higher risk in young…
FDA asks Covid vaccine makers to add more myocarditis data to labels
FDA requests Moderna, Pfizer/BioNTech add safety warnings about myocarditis risk to COVID-19 vaccines, with specific rates for different age groups, including higher risk in young…
In his first major policy rollout, Vinay Prasad looks to challenge existing ‘dogma’ on Covid vaccines
Two weeks into his tenure leading the FDA’s biologics center, Vinay Prasad has made his mark with a new framework for approving future Covid-19 vaccines…
Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent
Biotech execs express concerns over FDA changes, NIH cuts, and Trump’s tariffs. Industry confidence low amid poor funding environment and dead IPO market in 2025.
Why Regeneron is buying 23andMe
Regeneron has a long history with its gene-sequencing efforts, which likely provides some hints as to why the biotech saw the 23andMe deal as worthwhile.
Regeneron plans to buy 23andMe for $256M
Regeneron is acquiring 23andMe through a court-supervised sale, following 23andMe’s bankruptcy filing and recent struggles.
